logo banner home news contact
nav

news

events

News

FOR MEDIA
Argos Therapeutics, Inc. is developing breakthrough immunotherapies that target unique features of a patient’s disease. This new generation of personalized therapeutics trains the immune system to recognize and attack diseases. Argos’ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. For inquiries, please contact [email protected]



LATEST NEWS & PRESS RELEASES

2013

Argos Therapeutics Announces Additional $17.5 Million of Series E Financing Bringing Total Commitment to $60 Million
Click for the full story

Argos Therapeutics to Present at the Elsevier Therapeutic Area Partnerships Meeting
Click for the full story

Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
Click for the full story

Argos Therapeutics Announces Globalization of Pivotal Phase 3 ADAPT Study for Personalized Cancer Immunotherapy
Click for the full story

JAIDS Study by Argos Therapeutics Evaluates Impact of Personalized Immunotherapy in HIV-Infected Patients
Click for the full story

Argos Therapeutics Secures $42.5 Million Financing, Funds Pivotal Phase 3 ADAPT Trial for Personalized Immunotherapy
Click for the full story

Argos Therapeutics Identifies Topical Formulation for Prolonged Graft Survival in Corneal Transplants
Click for the full story

Argos Therapeutics Announces Plans for HIV Eradication Study
Click for the full story

Leading HIV Researchers and Argos Therapeutics Highlight Importance of Immunotherapy in HIV Eradication Efforts
Click for the full story

Argos Therapeutics Announces US and Global Expansion for Ongoing Pivotal Phase 3 ADAPT Study for Personalized Immunotherapy
Click for the full story

Argos Confirms Improved RNA Amplification Protocol Enhances Quality of Antigen-Specific Immune Response
Click for the full story

Argos Therapeutics to Present at the 12th Annual Needham Healthcare Conference
Click for the full story

Argos Therapeutics Welcomes Jean Lamarre to Board of Directors
Click for the full story

Argos Therapeutics Validates Durability of AGS-003 Induced Immune Response in mRCC Patients
Click for the full story

Argos Therapeutics Announces Updated Phase 2 Data for AGS-003 Personalized Immunotherapy for Metastatic Renal Cell Carcinoma
Click for the full story

Argos Therapeutics to Present on Automated Manufacturing Process at 2013 Cell and Gene Therapy Forum
Click for the full story

Argos Therapeutics Enrolls Initial Patients in Pivotal Phase 3 ADAPT Study
Click for the full story

2012

Argos Therapeutics Study Confirms Optimal Quality Control Methods for Production of its RNA-Based Immunotherapies
Click for the full story

Southeast BIO Recognizes Argos Therapeutics with the “2012 Southeast BIO Deal of the Year: Venture Capital Transaction” Award
Click for the full story

Argos Therapeutics to Present at Noble Financial Capital Markets´ BIOX Life Sciences Exposition
Click for the full story

Argos Therapeutics Expands Global Patent Protection
Click for the full story

Argos Therapeutics to Present at the Stifel Nicolaus 2012 Healthcare Conference
Click for the full story

Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial
Click for the full story

Argos Therapeutics Presents Positive Phase 1a Data for AGS-009 in Patients with Lupus at 2012 EULAR Congress
Click for the full story

Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos´s Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Click for the full story

Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
Click for the full story

Argos Therapeutics Announces New Data Demonstrating Prolonged Overall Survival in a Phase 2 Study of its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Click for the full story

Argos Therapeutics Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
Click for the full story

2011

Argos Therapeutics´ Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System
Click for the full story

Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
Click for the full story

Argos Therapeutics to Participate in Panel Discussion on Innovative Approaches to HIV Vaccine Development and Immunotherapies at 2011 BIO International Convention
Click for the full story

Argos Therapeutics Presents New Phase 2 Data Showing its Arcelis™ Immunotherapy AGS-003 in Combination with Sunitinib Improves Progression-Free Survival (PFS) in Patients with Advanced Renal Cell Carcinoma (RCC)
Click for the full story

Argos Therapeutics´ Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination with Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Click for the full story

Argos Therapeutics´ Immunotherapy Platform Based on Recombinant Human Soluble CD83 Demonstrates Significant Promise For Solid Organ Transplantation
Click for the full story

Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Needham & Company 10th Annual Healthcare Conference and Leerink Swann Cancer Roundtable Conference
Click for the full story

Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics´ Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
Click for the full story

2010

Argos Therapeutics´ Arcelis™ HIV Immunotherapy Shows Feasibility to Generate Fully Functional Dendrtic Cells from Viremic Patients
Click for the full story

Argos Therapeutics Initiates Dosing of Patients in Phase 1 Clinical Trial of Monoclonal Antibody-Based Therapy for Treatment of Systemic Lupus Erythematosus
Click for the full story

Argos Therapeutics Initiates Dosing of Patients in Phase 2b Clinical Trial of Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients
Click for the full story

Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
Click for the full story

Argos Therapeutics to Present About the Implementation, Cost Effectiveness and Benefits of Automation for its Arcelis™ Immunotherapy at The Cell Therapy Industry Summit-2010
Click for the full story

Argos Therapeutics to Present a Corporate Overview, Prospects of its Arcelis™ Immunotherapy and Clinical Developments at 2010 Mid-Atlantic Bio
Click for the full story

Leading Renal Cell Carcinoma (RCC) Researchers to Discuss Novel Therapies, Promise of Personalized Immunotherapy in Webinar Hosted by Argos Therapeutics
Click for the full story

Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
Click for the full story

Argos Therapeutics´ Arcelis™ Immunotherapy for Renal Cell Carcinoma Demonstrates Encouraging Results in Phase 2 Combination Study with Sunitinib
Click for the full story

Results From Argos Therapeutics´ Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Click for the full story

Argos Therapeutics´ Arcelis™ HIV Immunotherapy Demonstrates Significant Reduction in Viral Load and Delay in Viral Rebound Kinetics in Interim Analysis of Phase 2 Study
Click for the full story

Argos Therapeutics Presents Positive Phase 2 Data for Arcelis™ Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
Click for the full story

Argos Therapeutics Presents Phase 2a Data for Arcelis™ HIV Program Demonstrating Positive Impact on Viral Diversity and Viral Load
Click for the full story

Argos Therapeutics Presents New Phase 2a Data on the Impact of Arcelis™ HIV Program on Viral Genetic Diversity
Click for the full story

Argos Therapeutics Presents Positive Phase 2 Data of its Arcelis™ Personalized Immunotherapy Platform in Metastatic RCC at ASCO GU Symposium
Click for the full story

Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis™ HIV Program in Clinical Immunology
Click for the full story

Argos Therapeutics Appoints Jeffrey D. Abbey President and Chief Executive Officer
Click for the full story

2009

Argos Therapeutics Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis™ HIV Program at the AIDS Vaccine 2009 Conference
Click for the full story

Argos Therapeutics Publishes Research on the Immunosuppressive Properties of HIV
Click for the full story

Argos Therapeutics Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the American Transplant Congress
Click for the full story

Argos Therapeutics Presents Research Validating Feasibility and Safety of its Arcelis™ Personalized Immunotherapy Platform for HIV
Click for the full story

Argos Therapeutics Presents Research on the Development and Evaluation of Immunotherapies for HIV
Click for the full story

Argos Therapeutics Presents Positive Transplantation and Immunosuppression Data for Soluble CD83 at the Canadian Society of Transplantation Congress
Click for the full story

2008

Argos Therapeutics Completes $35.2 Million Series C Financing
—Supports Continued Progress in Arcelis™ Personalized Immunotherapy Programs in HIV, Oncology and Novel Autoimmune Candidate Development—
Click for the full story

Argos Therapeutics to Discuss Personalized Dendritic Cell Immunotherapy Process at iSBTc Annual Meeting
—Company to Provide Details on IL-12 as an Immunopotency Marker in a Poster Presentation—
Click for the full story

Argos Therapeutics Publishes Novel Approach to Improving Stimulation of Immunotherapeutic Pathways via Dendritic Cells
Click for the full story

Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy-Paper Published in the Journal of Immunotherapy-
Click for the full story

Argos Therapeutics Publishes Approach to Improving Dendritic Cell-Based Immunotherapy-Paper Published in the Journal of Immunotherapy-
Click for the full story

Argos Therapeutics Initiates Phase 2 Trial in Renal Cell Carcinoma for its Arcelis™Personalized Immunotherapy Platform
Click for the full story

Argos Therapeutics to Discuss Automated Manufacturing Process for its Arcelis™ Personalized Immunotherapy Platform
Click for the full story

Argos Therapeutics and Université de Montréal Present Novel Method to Create Personalized Immunotherapy Treatments that Stimulate HIV-Specific T Cells
Click for the full story

Argos Therapeutics´ Arcelis™ Personalized Immunotherapy Platform in HIV Achieves Primary Endpoint in Phase 1 Trial
Click for the full story

Argos Therapeutics to Discuss Automated Manufacturing Process for Personalized Immunotherapy at IBC Next Generation Vaccines Conference
Click for the full story

Argos Therapeutics Announces Three Presentations at BIO 2008 International Convention
Click for the full story

Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by Soluble CD83 at the American Transplant Congress
Click for the full story

Argos Therapeutics Initiates Phase 2 Proof-of-Concept Trial for its Arcelis™ Personalized Immunotherapy Platform in HIV
Click for the full story

Argos Therapeutics Secures $35.2 Million Series C Financing
—Funding to Advance Arcelis™ Personalized Immunotherapy Programs in HIV and Cancer, and Novel Immunosuppressant, CD83—
Click for the full story

Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis™ Platform in HIV at Keystone Symposia
Click for the full story

Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by Soluble CD83 at the Canadian Society of Transplantation Congress
Click for the full story

Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy Treatments for HIV
Click for the full story

2007

Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Click for the full story

Argos Therapeutics Presents Positive Data on its Personalized Cancer Immunotherapy Programs at ISTBC Meeting
Click for the full story

Argos Therapeutics featured in Fierce Biotech
Click for the full story

Argos Therapeutics´ Scientific Founder Ralph Steinman, M.D., Receives Lasker Award for Basic Medical Research
Click for the full story

Argos Therapeutics Presents Immunosuppression Data for Soluble CD83 at the American Society of Transplantation Congress 2007
Click for the full story

Argos Therapeutics Raises $5.0 Million in Debt Financing
Click for the full story

Argos Therapeutics Awarded U.S. Patent for CD83 Protein for Use in Immunological Disorders
Click for the full story

Personalized Immunotherapy Clinical Trial Initiated in HIV Patients with Argos Therapeutics´ AGS-004
Click for the full story

2006

Argos Therapeutics Appoints Dr. John Bonfiglio Chief Executive Officer
Click for the full story

Argos Therapeutics Awarded NIH Contract to Further Develop HIV Immunotherapy Candidates — $21 Million Contract for Novel Immunotherapies
Click for the full story

Argos Therapeutics Initiates Phase I/II Trial with AGS-003 Personalized Immunotherapy in Advanced Kidney Cancer
Click for the full story

Argos Therapeutics and Novo Nordisk Announce Agreement to Develop Treatment for Systemic Autoimmune Disorders
Click for the full story

Argos, Beckman Coulter Sign License Agreement: CD83 Licensure to Advance Work on Autoimmune Disorders, Transplant Rejection Therapy
Click for the full story

2005

Argos Therapeutics and DC Bio Corp. Announce New Clinical Trial to Begin for Chronic Lymphocytic Leukemia Using Argos´ Personalized Dendritic Cell Vaccine
Click for the full story

Argos Therapeutics Data From Kidney Cancer Vaccine Phase I/II Study To Be Presented At Two Upcoming Oncology Conferences
Click for the full story

Argos Therapeutics Receives $1.0 Million Grant for Lupus Research
Click for the full story

2004

Merix Bioscience Changes its Name to Argos Therapeutics
Click for the full story

Merix Bioscience Announces New Leadership and Board Members
Click for the full story

Merix and Kirin to Develop Personalized Dendritic Cell Vaccines for Cancer, HIV and Other Diseases
Click for the full story

Merix Bioscience Launches Trial for New Kidney Cancer Vaccine
Click for the full story

Merix Bioscience Announces Agreement with Geron Corporation for Development of Cancer Vaccines
Click for the full story

2001

Merix Bioscience Licensed Patent to Use RNA Loaded Cells to Treat Cancers and Pathogen Infections
Click for the full story

Merix Bioscience Appoints World's Leading Dendritic Cell Researchers to Expert Advisory Committee
Click for the full story

Merix Bioscience Establishes European Subsidiary
Click for the full story

Merix Bioscience Completes $39.5 Million Private Financing
Click for the full story